AA
CSTL icon

AlphaCentric Advisors’s Castle Biosciences CSTL Stock Holding History

AlphaCentric Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$407K Buy
+9,500
New +$496K 0.12% 69

Other funds holding CSTL

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AlphaCentric Advisors's CSTL Position: Q4 2021 in Review

AlphaCentric Advisors opened a new position in Castle Biosciences (CSTL) in Q4 2021: 9,500 shares worth $407K. The stake represents 0.12% of the portfolio and ranks #69 among its holdings.

159 funds tracked by Wall St. Rank hold CSTL as of Q4 2021.

  • AlphaCentric Advisors held 9,500 shares of Castle Biosciences worth $407K as of Q4 2021.
  • Castle Biosciences was a new AlphaCentric Advisors position in Q4 2021.
  • Castle Biosciences made up 0.12% of AlphaCentric Advisors's portfolio in Q4 2021, its #69 holding.
  • 159 funds tracked by Wall St. Rank held Castle Biosciences as of Q4 2021.

Based on AlphaCentric Advisors's 13F filing for Q4 2021, filed 25 Feb 2022.